Skip to main content
Sign In

Welcome to the Barbara Davis Center for Diabetes at the University of Colorado School of Medicine on the Anschutz Medical Campus in Aurora, Colorado.

Barbara Davis Center Banner Image
 

Clinical Research: Safety Study Monitoring Bayhill-3021 in Type 1 Diabetes Mellitus

The BHT Research Study


 

Principal Investigator: Peter Gottlieb, COMIRB #: 06-0627

  • The BHT Research Study is looking for people diagnosed with type 1 diabetes who may still producing some of their own insulin.
  • This research study will test the medication BHT-3021 to see if it is safe.
  • Secondarily, the research study will see if BHT-3021 can help maintain the body’s ability to produce some insulin.

Why should you consider this study?

  • You will be part of a research study to see if we can stop your slow down your  body’s attack of on the cells that produce insulin.
  • If the study drug is successful, you may have an easier time managing your diabetes.
  • The information from this study may help other people with diabetes.

Who can sign up for this study?

  • People who have been diagnosed with Type 1 Diabetes.
  • 18 - 45 years old.
  • 40 years old or less at the time of diagnosis with type 1 diabetes.
  • People who may be producing some of their own insulin.

What will happen in this study?

  • You will be assessed for general health and diabetes care.
  • If you qualify, you will receive 12 weekly treatments with study medication or fake medication.
  • If you receive the fake medication, you can receive the study medication after one year.
  • You will be monitored for 2-5 years to look at your overall diabetes health.

Who should I call with questions or to schedule an appointment?

Sandy Barry: 303-724-7501 or Sandra.Barry@ucdenver.edu
Lisa Meyers: 303.724.6893 or Lisa.Meyers@ucdenver.edu